(Q34474126)

2 August 2017

1 reference

title

Treatment options for deep venous thrombosis (English)

1 reference

2 August 2017

0 references

1 reference

Brown DF

1

1 reference

2 August 2017

publication date

1 November 2001

1 reference

Emergency medicine clinics of North America

2 August 2017

published in

1 reference

2 August 2017

volume

19

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

913-23, vi

1 reference

Clinical experience with superior vena caval Greenfield filters

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Clinical significance of free-floating venous thrombi

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Deep venous thrombosis: early discharge strategies and outpatient management

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Outpatient treatment of deep vein thrombosis: translating clinical trials into practice

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Physician-guided treatment compared with a heparin protocol for deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Contemporary use of and future roles for heparin in antithrombotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Management of deep venous thrombosis and pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Twenty-year clinical experience with the Greenfield filter

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

The successful application of a heparin nomogram in a community hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Upper extremity deep venous thrombosis: a case report and review of current diagnostic/therapeutic modalities

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Antithrombotic therapy for venous thromboembolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Greenfield vena caval filter: rationale and current indications

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Late results of iliofemoral venous thrombectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Early outcome after isolated calf vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Acute venous thrombosis. Therapeutic choices for superficial and deep veins

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Is embolic risk conditioned by location of deep venous thrombosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Free-floating iliofemoral thrombus. A risk of pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Upper-extremity deep-vein thrombosis: thrombolytic therapy with anistrepalase

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Venous thrombectomy for iliofemoral vein thrombosis--10-year results of a prospective randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

The Long-Term Clinical Course of Acute Deep Venous Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Low-molecular-weight heparin--an opportunity for home treatment of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Treatment options for venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Thrombolytic therapy for venous thromboembolism. Utilization by practicing pulmonologists

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Extension of saphenous thrombophlebitis into the femoral vein: demonstration by color flow compression sonography

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

Criteria for outpatient management of proximal lower extremity deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8627%2805%2970226-1

7 January 2021

10.1016/S0733-8627(05)70226-1

Identifiers

DOI

1 reference

2 August 2017

1 reference